Armstrong, A.W., Lebwohl, M., Bagel, J., Schlesinger, T., Banerjee, S., Kisa, R.M., Scharnitz, T., Hoyt, K. and Strober, B. 2023. Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in moderate to severe plaque psoriasis: efficacy by baseline body surface area (BSA) involvement and baseline Psoriasis Area and Severity Index (PASI). SKIN The Journal of Cutaneous Medicine. 7, 2 (Mar. 2023), s120. DOI:https://doi.org/10.25251/skin.7.supp.120.